71 results
8-K
EX-99.1
URGN
UroGen Pharma Ltd.
13 Aug 24
UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights
8:01am
not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract.
Before receiving JELMYTO, tell your healthcare … not become pregnant during treatment with JELMYTO. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during
8-K
EX-99.1
URGN
UroGen Pharma Ltd.
13 Jun 24
Regulation FD Disclosure
10:51am
available to UroGen as of the date of this presentation. Not for promotional use with healthcare professionals. 2
UROGEN IS UNIQUELY POSITIONED … can be Compelling clinical data administered by a trained LG-IR-NMIBC market package from 4 trials and healthcare professional in alone ripe for 593
8-K
EX-99.1
hzazuc2
13 May 24
ENVISION data expected to support completion of UGN-102 NDA in Q3 2024
8:01am
8-K
EX-99.1
b2uiv2qc gn4xop
14 Mar 24
UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
8:16am
8-K
EX-99.1
j5l0ra7p
4 Mar 24
Regulation FD Disclosure
7:00am
8-K
aczwswww1ig6bti9u
7 Feb 24
Regulation FD Disclosure
4:15pm
8-K
EX-99.1
kdvc8icwa41cqx82af1a
7 Feb 24
Regulation FD Disclosure
4:15pm
8-K
EX-99.1
juets 2wu
14 Nov 23
UroGen Pharma Reports Third Quarter 2023 Financial Results
12:00am
8-K
EX-99.1
giw7 2kfhr82it7
10 Aug 23
UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments
8:01am
8-K
EX-10.1
mxho4c 53
27 Jul 23
UroGen Announces $120 Million Private Placement of Ordinary Shares
9:57am
8-K
EX-99.2
cw37f97prmi3g qry7i
27 Jul 23
UroGen Announces $120 Million Private Placement of Ordinary Shares
9:57am